IDEAL: In the footsteps of IMMLEP and THELEP

Leprosy Review

Volumn 80, Issue 3, 2009, Pages 236-245

  Brennan, Patrick J ^a,b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Heiser Program for Research on Leprosy and Tuberculosis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BCG VACCINE; CARBOHYDRATE; GAMMA INTERFERON; GLYCOLIPID; LEPROSY VACCINE; LIVE VACCINE; MINOCYCLINE; MONOCLONAL ANTIBODY; OFLOXACIN; RECOMBINANT PROTEIN; RIFAMPICIN;

ANTIGENICITY; ARMADILLO; BACTERIAL TRANSMISSION; CELLULAR IMMUNITY; EDITORIAL; FOOT PAD; GENE LOCUS; GENETIC RECOMBINATION; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION PREVENTION; LEPROSY; LEPROSY CONTROL; LIVER; LYMPH NODE; LYMPHOCYTE CLONE; MYCOBACTERIUM LEPRAE; SINGLE DRUG DOSE; SPLEEN; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

BACTERIAL VACCINES; HUMANS; LEPROSY; MYCOBACTERIUM LEPRAE; TROPICAL MEDICINE; WORLD HEALTH ORGANIZATION;

EID: 73249128358     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (62)

1. Shepard CC. The experimental disease that follows the injection of human leprosy bacilli into footpads of mice. J Exp Med, 1960; 112: 445-454.
2. Kirchheimer WF, Storrs EE, Binford CH. Attempts to establish the armadillo (Dasypus novemcinctus linn.) as a model for the study of leprosy. II. Histopathologic and bacteriologic post-mortem findings in lepromatoid leprosy in the armadillo. Int J Lepr, 1972; 40: 229-242.
3. Draper P. Protocol 1/79: Purification of M. leprae. Annex 1 of the Enlarged Steering Committee for Research on the Immunology of Leprosy (IMMLEP) Meeting of 7-8 February 1979. World Health Organization, Geneva, 1979; p. 4.
4. WHO. Sixth Programme Report: Chapter 8, Leprosy. TDR/PR-6/83.8 - LEP, 1983; 209-296.
5. WHO. Report of the Seventh Meeting of the Scientific Working Group (SWG) on the Immunology of Leprosy; Geneva, June 9-11, 1987. TDR/IMMLEP/SWG (7)/87.3; 1987: 3-21.
6. Bloom BR, Mehra V. Immunological Unresponsiveness in Leprosy. Immunological Reviews, 1984; 80: 5-28.
7. Fine PEM, Ponnighaus JM, Maine NP et al. The protective efficacy of BCG against leprosy in Northern Malawi. The Lancet, 1986; 2: 499-502.
8. WHO. Testing of purified armadillo-derived M. leprae in man. Document finalized by the IMMLEP Steering Committee at its meeting, 10-12 June 1981. TDR/IMMLEP/SC/TEST/81.1; 1981: 2-34.
9. WHO. Report of the Second Joint Meeting of the Scientific Working Groups on the Immunology of Leprosy (IMMLEP) and Immunology of Tuberculosis (IMMTUB). Geneva June 4-5 1984, TDR/IMMLEP-IMMTUBSWG (2)/84.3: 1984: 1-9.
10. WHO. Vaccination trials against leprosy: A meeting of the epidemiology subgroup of the Scientific Working Group on the Immunology of Leprosy; Geneva, February 11-13 1985, TDR/IMMLEP/EPD/85.3: 1985:1-18.
11. Convit J, Sampson C, Zuniga M et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. The Lancet, 1992; 339: 446-450.
12. Karonga Prevention Trial Group. Randomized controlled trial of single BCG, repeated BCG or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. The Lancet, 1996; 384: 17-24.
13. Gupte MD, Vallishayee RS, Anantharaman DS et al. Comparative leprosy vaccine trial in South India. Indian J Lepr, 1998; 70: 369-388.
14. IMMYC Steering Committee. WHO analysis of vaccines prepared from armadillo-derived M. leprae; results of an inter-laboratory study coordinated by the World Health Organization. Int J Lepr, 1995; 63: 48-55.
15. Almeida JG, Christian M, Chacko CJG et al. Studies on dapsone-resistant Mycobacterium leprae in leprosy patients of Guiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. Lepr Rev, 1983; 54: 185-191.
16. Almeida JG, Chacko CJG, Christian M et al. DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. Int J Lep, 1983; 51: 366-373.
17. Almeida JG, Chacko CJG, Christian M. The significance of dapsone (DDS) - resistant Mycobacterium leprae in untreated patients. Int J Lepr, 1983; 51: 374-377.
18. Ji B, ChenJ, Zhang J et al. Secondary dapsone-resistant leprosy in Shanghai Municipality. Lepr Rev, 1983; 54:197-202.
19. Pattyn SR, Yuda A, Sansarricq H et al. Prevalence of secondary dapsone-resistant leprosy in Upper Volta. Lepr Rev, 1984; 51: 54-63.
20. Ji B. Drug resistance in leprosy - a review. Lepr Rev, 1985; 56: 265-278.
21. WHO. Report of the fourth meeting of the scientific working group on the chemotherapy of leprosy. Geneva, April 18-19 1983, TDR/THELEP-SWG(4)/83.3: 1-34.
22. WHO. Report of the eleventh and twelfth meetings of the steering committee of the scientific working group on the chemotherapy of leprosy. Geneva, March 30-31 and October 10 1982, TDR/THELEP-SC (11-12)/82.3: 1-6.
23. WHO. Report of the thirteenth and fourteenth meetings of the steering committee of the scientific working on chemotherapy of leprosy. Geneva, April 20-21 and October 11-12 1983, TDR/THELEP-SC (13-14)/83.3: 1-6.
24. WHO. Minutes of the meeting of the Steering Committee on Immunology of Mycobacteria (IMMYC). Geneva, April 27-29 1993, MM/PVD/93.5: 1-77.
25. WHO. Minutes of the meeting of the Steering Committee on Immunology of Mycobacterial Diseases. Geneva, April 24-26 1994, GPV/VRD/94.6: 18-66.
26. Engers HD, Abe M, Bloom BR et al. Results of a World Health Organization-sponsored workshop on monoclonal antibodies to Mycobacterium leprae. Infect Immun, 1985; 48: 603-605.
27. Engers HD, Houba V, Bennedsen J et al. Results of a World Health Organization-sponsored workshop on monoclonal antibodies to Mycobacterium leprae. Infect Immun, 1985; 48: 718-720.
28. Khanolkar-Young S, Kolk AHJ, Andersen AB et al. Results of the third immunology of leprosy/immunology of tuberculosis antimycobacterial monoclonal antibody. Infect Immun, 1992; 60: 3925-3927.
29. Gillis TP, Williams DL. Polymerase chain reaction and leprosy. Int J Lepr, 1991; 59: 311-316.
30. Cho S-N, Yanagihara DL, Hunter SW et al. Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun, 1983; 41: 1077-1083.
31. Cole ST, Eiglmeier K, Parkhill J et al. Massive gene decay in the leprosy bacillus. Nature, 2001; 409: 1007-1011.
32. Young RA, Mehra V, Sweetser D et al. Genes for the major protein antigens of leprosy parasite Mycobacterium leprae. Nature, 1985; 316: 450-452.
33. Young RA, Bloom BR, Grosskinsky CM et al. Dissection of Mycobacterium tuberculosis antigens using recombinant DNA. Proc Natl Acad Sci USA, 1985; 82: 2583-2587.
34. Thole JEM, Dauwerse HG, Das PK et al. Cloning of Mycobacterium bovis BCG DNA and expression of antigens in Escherichia coli. Infect Immun, 1985; 50: 800-806.
35. Young DB, Kaufmann SHE, Hermans PWM, Thole JER. Mycobacterial protein antigens: a compilation. Mol Microbiol, 1992; 6: 133-145.
36. WHO. Structural changes at WHO Headquarters; global elimination project retains its independence. Lepr News, 1999; 8: 1-4.
37. WHO. WHO expert committee on leprosy. Seventh report; 1998; Geneva, Switzerland.
38. WHO. Action programme for the elimination of leprosy. Status Report, 1998.
39. WHO. Report of a special meeting of the leprosy elimination advisory group (LEAG) with potential partners; Geneva, April 12, 13 1999. WHO/LEP/99.1, 1999: 1-7.
40. WHO. Report on the first meeting of the WHO technical advisory group on elimination of leprosy; Geneva, May 2, 3 2000; WHO/CDS/CPE/CEE/2000.4, 2000; 1-36.
41. WHO. Report on the second meeting of the WHO technical advisory group on elimination of leprosy; New Delhi, February 1, 2001; WHO/CDS/CPE/CEE/2001. 21, 2001; 1-16.
42. WHO. First meeting of the global alliance for elimination of leprosy (GAEL); January 30, 31, 2001; New Delhi, India. WHO/CDS/CPE/CEE/2001.27; 2001: 4-43.
43. WHO. The final push towards elimination of leprosy, Strategic Plan 2000-2005. WHO/CDS/CPE/CEE/2000.1; 2000: 1-13.
44. WHO. Report on the sixth meeting of the WHO technical advisory group on elimination of leprosy; Geneva, February 9, 10, 2004. WHO/CDS/CPE/CEE/2004. 41; 2004: 1-21.
45. WHO. Global Strategy for further reducing the leprosy burden and sustaining leprosy control activities (2006-2010); operational guidelines. WHO Regional Office for South-East, Asia New Delhi. WHO/SEA/GLP/2006.2; 2006: 1-49.
46. Curtiss R, III, Blevan S, Cooper K et al. Leprosy research in the post-genome era. Lepr Rev, 2001; 78: 8-22.
47. Levy L (editor). Leprosy research at the new millennium; a workshop sponsored by the International Federation of Anti-Leprosy Associations (ILEP), 26-28 June 2000, Association Francaise Raoul Follereau, Paris, France. Lep Rev, 2000; 71 (supplement): S1-S192.
48. ILA. Report of the International Leprosy Association Technical Forum. Lep Rev, 2002; 73 (supplement): S1-S62.
49. Richardus JH, Habbema JDF. The impact of leprosy control on the transmission of M. leprae: is elimination being attained? Lepr Rev, 2007; 78: 330-337.
50. WHO. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec, 2008; 83: 293-300.
51. Aseffa A, Brennan P, Dockrell H et al. Report of the first meeting of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) Consortium held at Armauer Hansen Research Institute, ALERT, Addis Ababa, Ethopia on 24-27 October 2004. Lepr Rev, 2005; 76: 147-159.
52. Geluk A, Spencer JS, Bobosha K et al. From genome to leprosy diagnostics: from in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol, 2009; 16: 352-359.
53. Cole ST, Supply P, Honoré H. Repetitive sequences in Mycobacterium leprae and their impact on genome plasticity. Lepr Rev, 2001; 72: 449-461.
54. Matsuoka M, Maeda S, Kai M et al. Mycobacterium leprae typing by genomic diversity and global distribution of genotypes. Int J Leprosy, 2000; 68: 121-128.
55. Shin YC, Lee H, Lee H et al. Variable numbers of TTC repeats in Mycobacterium leprae DNA from leprosy patients and use in strain differentiation. J Clin Microbiol, 2000; 38: 4535-4538.
56. Truman R, Fontes AB, De Miranda AB et al. Genotypic variation and stability of four variable-number tandem repeats and their suitability for discriminating strains of Mycobacterium leprae. J Clin Microbiol, 2004; 42: 2558-2565.
57. Groathouse NA, Rivoire B, Kim H, et al. Multiple polymorphic loci for molecular typing of strains of Mycobacterium leprae. J Clin Microbiol, 2004; 42: 1666-1672.
58. Young SK, Taylor GM, Jain S et al. Microsatellite mapping of Mycobacterium leprae populations in infected humans. J Clin Microbiol, 2004; 42: 4931-4936.
59. Zhang L, Budiawan T, Matsuoka M. Diversity of potential short tandem repeats in Mycobacterium leprae and application for molecular typing. J Clin Microbiol, 2005; 43: 5221-5229.
60. Weng XM, Wang Z, Liu J et al. Identification and distribution of Mycobacterium leprae genotypes in a region of high leprosy prevalence in China: a 3-year molecular epidemiological study. J Clin Microbiol, 2007; 45: 1728-1734.
61. Kimura M, Sakamuri RM, Groathouse NA et al. Rapid variable-number tandem-repeat genotyping for Mycobacterium leprae clinical specimens. J Clin Microbiol. 2009; 47: 1757-1766.
62. Monot M, Honoré N, Garnier T et al. On the origin of leprosy. Science, 2005; 308: 1040-1042.